SynthesisBMC pediatrics2024
Aromatase inhibitors for short stature in male children and adolescents treated with growth hormone: a meta-analysis of randomized controlled trials.
Synthesis in BMC pediatrics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Aromatase enzyme deficiency in an adult male patient and the effects of estrogen replacement therapy: a rare cause of tall stature.Hormones (Athens, Greece) · 2025Article
- Combination therapy of GnRHa, RhGH and anastrozole to improve final adult height deficit in CAH children with CPP.BMC pediatrics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whether the addition of aromatase inhibitors (AIs) to recombinant human growth hormone (rhGH) could yield additional benefit for short stature is controversial. We aimed to assess the effects of combined AIs and rhGH versus those of rhGH alone for short stature using a meta-analytic approach. The PubMed, Embase, and the Cochrane library electronic databases were searched systematically for eligible randomized controlled trials (RCTs) from inception until December 2021. The pooled effect estimates (weighted mean difference [WMD] and odds ratio [OR]) with 95% confidence intervals (CIs) were calculated using a random-effects model. Eight RCTs that provided data on 433 participants were selected. The addition of AIs to rhGH, compared with rhGH alone, resulted in higher growth velocity (WMD: 3.19 cm/year; 95% CI: 2.75-3.63; P < 0.001), higher predicted adult height (WMD: 5.50 cm; 95% CI: 3.52-7.49; P < 0.001), and younger bone age (WMD: -0.80 years; 95% CI: -1.06--0.54; P < 0.001). There were no significant differences between the groups for insulin-like growth factor I (WMD: 0.85 nmol/L; 95% CI: -2.08-3.79; P = 0.569), serum estradiol level (WMD: -19.19 pmol/L; 95% CI: -46.25-7.88; P = 0.165), and serum testosterone level (WMD: 14.88 nmol/L; 95% CI: -14.13-43.88; P = 0.315). There was no significant difference between the groups for the risk of adverse events (OR: 1.08; 95% CI: 0.44-2.66; P = 0.873). This study found that the addition of AIs to rhGH had greater benefits for growth velocity, predicted adult height, and bone age. The safety profiles were comparable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.